Alzamend Neuro Surges to 159th in Daily Rankings with $54.3 Million Turnover

On May 29, 2025, Alzamend Neuro (ALZN) experienced a significant surge in trading volume, with a turnover of $54.3 million, marking a 4385.30% increase from the previous day. This substantial rise in trading activity placed ALZN at the 159th position in the daily stock market rankings, reflecting a 63.86% increase in stock price.

Alzamend Neuro has initiated dosing in its Phase II clinical trial of AL001, a novel lithium formulation, at Massachusetts General Hospital. The study aims to compare AL001's brain absorption and blood levels against existing lithium carbonate products in healthy subjects. Topline data is expected by the end of 2025.

AL001 represents a potential breakthrough in lithium-based treatments, as previous mouse studies demonstrated improved brain absorption with lower blood levels, potentially eliminating the need for therapeutic drug monitoring (TDM). This advancement could benefit over 43 million Americans affected by Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD.

The trial follows the successful development of a novel head coil by Tesla Dynamic Coils BV, which is crucial for the study's execution. Alzamend's first Phase II patient dosing for AL001 marks significant progress in developing a potentially safer lithium treatment with better brain targeting.

Alzamend Neuro has reached a critical milestone with the dosing of its first patient in the Phase II "Lithium in Brain" study for AL001 at Massachusetts General Hospital. This head-to-head comparison against existing lithium carbonate treatments is designed to evaluate a fundamental pharmacokinetic question: can AL001 achieve higher brain concentrations while maintaining lower blood levels of lithium?

The scientific rationale here is compelling. Conventional lithium salts, while effective for bipolar disorder, face significant clinical limitations due to their narrow therapeutic window, requiring regular therapeutic drug monitoring (TDM) and multiple daily doses. This monitoring burden substantially restricts lithium's clinical utility despite its established efficacy.

AL001's preclinical mouse data suggests a potentially transformative pharmacokinetic profile - better brain absorption with lower systemic exposure. If replicated in humans, this could eliminate the need for burdensome TDM and reduce kidney and thyroid toxicities that limit current lithium use.

The study design using healthy volunteers is methodologically sound, establishing baseline pharmacokinetic parameters before moving to patient populations. The innovative head coil developed by Tesla Dynamic Coils BV likely enables more precise measurement of brain lithium concentrations.

With topline data expected by year-end 2025, this represents a critical value-driving catalyst. The company is pursuing multiple high-value indications including Alzheimer's, bipolar disorder, major depression, and PTSD - a potential combined patient population exceeding 43 million Americans.

If successful, AL001 could significantly expand lithium's clinical utility across neuropsychiatric conditions by addressing the primary limitations of current formulations - monitoring burden and toxicity profiles.